Financial Data and Key Metrics Changes - The company recognized $400,000 in revenue during Q1 2025, down from $600,000 in Q1 2024, with revenue being non-cash based on amortization of payments from a licensing arrangement [40] - Research and development (R&D) expenses increased by 43% to $76.2 million in Q1 2025 compared to the same period in 2024, primarily due to additional personnel and higher manufacturing costs [40] - Selling, general, and administrative (SG&A) expenses rose by 71% to $35.5 million in Q1 2025, driven by growth to support ongoing programs and the planned commercial launch of paltusotine [41] - Cash used in operations for Q1 2025 was $88.5 million, compared to $52.9 million in Q1 2024, with expectations of cash used in operations for 2025 between $340 million and $380 million [42] - The company ended Q1 2025 with approximately $1.3 billion in cash, cash equivalents, and investments, expected to fund operations into 2029 [42] Business Line Data and Key Metrics Changes - The company is focused on the anticipated commercial launch of paltusotine, which is expected to significantly improve treatment for patients with acromegaly [8][10] - The pipeline includes two late-stage candidates and three additional candidates in preclinical studies, indicating a robust development strategy [8] Market Data and Key Metrics Changes - The company is preparing for the launch of paltusotine in the U.S. and has engaged with payers, receiving positive feedback regarding the product's value proposition [18][23] - The anticipated launch strategy includes educating healthcare professionals and patients, with a focus on addressing the unmet needs in acromegaly treatment [12][16] Company Strategy and Development Direction - The company aims to become a fully integrated global commercial organization, with a strong commitment to patient care and scientific innovation [8] - The strategic focus includes advancing a robust pipeline while preparing for the commercial launch of paltusotine, which is seen as a pivotal milestone [10][24] - The company is also exploring opportunities in the CAH (congenital adrenal hyperplasia) market with the development of adomelna [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory engagement with the FDA and the progress of clinical development activities [10][24] - The company remains optimistic about the potential uptake of paltusotine during the early launch phase, anticipating major interest from healthcare providers and patients [23] Other Important Information - The company has welcomed a new CFO, Toby Schulke, who brings extensive experience in transitioning R&D-focused companies into commercial organizations [9] - The company has launched the Kineticare patient support service platform to assist patients throughout their treatment journey [16][17] Q&A Session Summary Question: Can you discuss the powering of your primary endpoint and any data from cohort four? - Management indicated that the study is highly powered to detect significant differences between treatment and placebo groups, and cohort four is currently enrolling with no data available yet [46][48] Question: Is the CALM CAH study design approved by the FDA for registration? - The protocol was developed with input from the FDA, and the company expects to discuss the indication statement based on the data collected [51][54] Question: What is the rationale for testing the primary endpoint at a single time point? - Management explained that responder analyses are typically conducted at single points in time due to variability in biochemical markers, and they are confident in achieving the endpoint [57][58] Question: What is the rationale for morning versus evening dosing in cohort four? - The company aims to explore the convenience of morning dosing while considering the diurnal rhythm of CAH patients [61][62] Question: How is the launch strategy different in Europe compared to the U.S.? - The European markets are more concentrated in terms of patient populations, and the company is preparing for a launch in Germany while considering Brazil for expansion [64][68]

Globus Medical (GMED) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Brian Kearns - SVP - Corporate Development & IRDaniel Scavilla - President & CEOKeith Pfeil - CFO & COOPhillip Dantoin - Assistant Vice PresidentRichard Newitter - Managing DirectorMathew Blackman - Managing DirectorCaitlin Cronin - DirectorMatt Taylor - Managing Director Conference Call Participants Matthew Miksic - AnalystVikramjeet Chopra - AnalystShagun Singh Chadha - AnalystDavid Saxon - Senior AnalystNone - Analy ...

OneStream (OS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Annie Leschin - VP - Strategic Finance & IRTom Shea - Co - Founder, CEO & PresidentBill Koefoed - CFOJohn DiFucci - Senior Managing DirectorAdam Hotchkiss - VP - Emerging Software Equity ResearchKoji Ikeda - Director - Enterprise Software Equity ResearchRyan Krieger - VP - Software Equity ResearchSonak Kolar - Software Equity Research AssociateTerry Tillman - Managing DirectorSiti Panigrahi - Managing DirectorScott Berg - Man ...

BILL Holdings (BILL) Q3 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Karen Sansot - VP of Investor RelationsRené Lacerte - Founder, CEO & Chairperson of the BoardJohn Rettig - President & CFOIan Black - Equity Research AssociateDarrin Peller - Managing DirectorAlex Markgraff - Vice President - Equity ResearchAdib Choudhury - Senior Equity Research Associate Conference Call Participants Tien-tsin Huang - Senior AnalystKen Suchoski - Equity Research AnalystChris Quintero - AnalystAndrew Sc ...

TransMedics Group (TMDX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Laine Morgan - Associate Vice PresidentWaleed Hassanein - Founder, President, CEO & DirectorGerardo Hernandez - Chief Financial OfficerAllen Gong - Vice PresidentWilliam Plovanic - Managing Director - Equity ResearchJustin Wang - Equity Research AssociateChris Pasquale - Partner - Medical Devices & SuppliesSuraj Kalia - Managing DirectorJosh Jennings - Managing Director Conference Call Participants Samantha Munoz - ...

DoubleVerify (DV) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Tejal Engman - SVP - IRMark Zagorski - CEONicola Allais - CFOMatthew Swanson - Director - Equity ResearchAndrew Marok - DirectorAndrew Boone - Managing DirectorMark Kelley - MD - InternetJacob Armstrong - Vice President, Equity ResearchAlinda Li - Equity Research Associate Conference Call Participants Maria Ripps - Managing Director, Senior Research AnalystBrian Pitz - Managing Director and Senior AnalystOmar Dessouky - An ...

Alarm.com (ALRM) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Matthew Zartman - Vice President of Strategic Communications & Investor RelationsStephen Trundle - President & CEOKevin Bradley - CFOMatt Bullock - Equity Research AssociateAdam Tindle - Managing DirectorSaket Kalia - Managing DirectorBilly Fitzsimmons - VP - Equity ResearchMatthew Filek - Equity Research Associate Conference Call Participants Darren Aftahi - Senior Research Analyst-Internet, Media and Enabling Technologies ...

AvePoint (AVPT) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants James Arestia - VP - Investor RelationsTianyi Jiang - Co-Founder, CEO & DirectorJim Caci - Chief Financial OfficerJoe Vandrick - Associate Director - Equity ResearchJason Ader - Co-Group Head - Technology, Media & CommunicationsNehal Chokshi - Managing DirectorChirag Ved - Vice PresidentCole Erskine - Vice President - Equity ResearchBrett Knoblauch - Managing Director Operator Good day, and welcome to the Airfind Inc. First ...

CleanSpark (CLSK) Q2 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Harry Sudock - SVPZachary Bradford - CEO, President & DirectorGary Vecchiarelli - Chief Financial OfficerGregory Lewis - Managing Director Conference Call Participants Mike Colonnese - Managing Director & Senior Technology AnalystBrian Dobson - Managing Director & Senior Research AnalystPaul Golding - Senior Analyst - Life Style and PaymentsJohn Todaro - Senior Analyst Operator Good afternoon. My name is Jeannie, and I wil ...

ICU Medical (ICUI) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants John Mills - Managing PartnerVivek Jain - Chairman & Chief Executive OfficerBrian Bonnell - Chief Financial OfficerJayson Bedford - Managing Director - Medical TechnologyJoseph Conway - Equity Research Associate Conference Call Participants Brett Fishbin - Vice President & Equity Research AnalystLarry Solow - Partner & Managing director - Equity AnalystMichael Toomey - US Medtech Analyst Operator Good day, and welcome to ...